|
Market Closed -
Boerse Muenchen
16:43:50 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 0.4500 EUR | 0.00% |
|
0.00% | +51.26% |
| 09-11 | Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review | MT |
| 09-11 | Nicox S.A. Announces Acceptance Of NCX 470 NDA For Review In China | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 33.96M | - | - | - | ||
| 362B | |||||
| 64.74B | |||||
| 12.76B | |||||
| 7.53B | |||||
| 4.38B |
- Stock Market
- Stocks
- ALCOX Stock
- NXOA Stock
- Charts Nicox SA
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
